Skip to content

The number of targeted therapies and complexity of biomarker detection linked to these therapies has grown over the last decade. To accommodate it, the drug development process must also evolve. In this webinar, we will show how combining the power of molecular and immune profiling to drive molecular-based testing is improving stratification methods and patient outcomes. We will also showcase the impact of a scalable comprehensive assay and infrastructure in the context of drug development.

Jeffrey Conroy
Chief Scientific Officerand Director Genomics Technologies,
OmniSeq Inc., Roswell Park Comprehensive Cancer Center

 

Date & Time
Feb 9, 2021
Location
North America
Affiliation
OmniSeq Inc., Roswell Park Comprehensive Cancer Center
Presenter
Jeffrey Conroy Chief Scientific Officer and Director Genomics Technologies
Topic
Oncology
Watch Now